Management practice and drug related problems and its contributing factors among cervical cancer patients at oncologic center in Ethiopia: a hospital-based retrospective study

Loading...
Thumbnail Image
Authors
Kefale, Belayneh
Engidaw, Melaku Tadege
Tesfa, Desalegn
Molla, Mulugeta
Yismaw, Malede Berihun
Issue Date
2022-06-10
Type
Article
Language
en_US
Keywords
Drug-Related Problems , Cervical Cancer , Felege Hiwot Comprehensive Specialized Hospital , Ethiopia
Research Projects
Organizational Units
Journal Issue
Alternative Title
Abstract
Introduction: In cervical cancer therapy, there is a high prevalence of drug-related problems (DRPs) due to the high toxicity and complexity of most antineoplastic regimens. However, there is a paucity of data about DRPs among patients with cervical cancer in Ethiopia. Hence, the present study was aimed at investigating management practices and DRPs among patients diagnosed with cervical cancer. Methods: A registry-based retrospective cohort study was employed among cervical cancer patients at the oncology center of Felege Hiwot Comprehensive Specialized Hospital (FHCSH). All patients with a histologically confirmed diagnosis of cervical cancer from January 2016 to December 2020 were included. Relevant information was recorded by reviewing medical records. The possibility of DRPs was evaluated by comparing with standard guidelines. Logistic regression analysis was employed. Results: A total of 184 cervical cancer patients were included, with a mean age of 50.2±10.7 years. A total of 216 DRPs were identified from 93 cervical cancer patients, translating to a prevalence of 50.5% and a mean of 2.32±1.11 DRPs per patient. ADR (27.3%), DDI (25%), and the need for additional drug therapy (22.2%) were the most prevalent DRPs. DRPs were associated with the presence of co-morbidity (AOR = 4.23, 95% CI = 1.78–10.05, p = 0.001), complications (AOR = 2.99, 95% CI = 1.28–6.99, p = 0.011), being treated with ≥5 medications (AOR = 5.1, 95% CI = 2.38–10.95, p < 0.001), being stage II (AOR = 0.14, 95% CI = 0.02–0.90, p = 0.038), and stage III (AOR = 0.04, 95% CI = 0.01–0.32, p = 0.003). Conclusion: Cisplatin-based chemotherapy was the frequently used therapeutic option. Co-morbidity and complication status, number of medication and stage of cancer were significantly associated with DRPs. The study highlights the need of clinical pharmacy services to optimize drug therapy and reduce DRPs.
Description
Citation
Kefale, B., Engidaw, M. T., Tesfa, D., Molla, M., & Yismaw, M. B. (2022). Management Practice and Drug Related Problems and Its Contributing Factors Among Cervical Cancer Patients at Oncologic Center in Ethiopia: A Hospital-Based Retrospective Study. Therapeutics and clinical risk management, 18, 643–655. https://doi.org/10.2147/TCRM.S364923
Publisher
Therapeutics and Clinical Risk Management
Journal
Volume
Issue
PubMed ID
DOI
ISSN
EISSN